FTDZX Performance — Franklin Biotechnology Discovery Fund, Advisor Class
Data updated: 2026-09-25
FTDZX returned +17.19% year to date and +71.87% over one year to Jul 2026. Annualised returns are +27.96% over 3 years and +12.09% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $210, against $137 for the category, and to $172 over one year, against $137. Volatility over the past three years was 20.79% a year. In the 12 months to Jul 2026 the fund took in a net $28.8M, and assets reached $1.15B.
FTDZX Growth of $100
What $100 invested in Franklin Biotechnology Discovery Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FTDZX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $172 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $210 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $177 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $237 | $183 |
FTDZX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +17.19% |
| 1 year | +71.87% |
| 3 years (annualised) | +27.96% |
| 5 years (annualised) | +12.09% |
FTDZX Annual Returns
Calendar-year total returns of Franklin Biotechnology Discovery Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +17.19% |
| 2025 | +52.68% |
| 2024 | +4.27% |
| 2023 | +18.70% |
| 2022 | −12.44% |
| 2021 | −17.50% |
| 2020 | +30.22% |
| 2019 (Aug–Dec) | +13.71% |
FTDZX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.2% | +3.2% | −1.0% | +2.2% | +3.2% | +10.8% | −2.0% | — | — | — | — | — |
| 2025 | +2.9% | −1.4% | −5.9% | +1.2% | −3.3% | +2.2% | +9.1% | +6.8% | +11.2% | +13.2% | +10.9% | −1.6% |
| 2024 | +4.9% | +8.0% | −1.5% | −6.5% | +2.4% | +2.5% | +6.3% | +1.8% | −1.6% | −2.2% | −2.2% | −6.5% |
| 2023 | +5.4% | −4.7% | +0.5% | +4.0% | −3.4% | +1.5% | +2.8% | −0.9% | −3.5% | −5.7% | +4.2% | +19.5% |
| 2022 | −10.0% | −3.7% | +4.7% | −8.7% | −6.7% | +3.6% | +3.2% | +0.1% | −1.4% | +4.3% | +6.8% | −3.7% |
| 2021 | +0.3% | +1.0% | −6.7% | +0.9% | −5.6% | +6.0% | −5.3% | +5.1% | −4.9% | −1.5% | −7.9% | +0.6% |
| 2020 | −4.5% | +0.8% | −9.0% | +13.9% | +9.9% | +3.2% | +0.5% | +0.1% | +3.1% | −4.2% | +11.8% | +3.6% |
| 2019 | — | — | — | — | — | — | — | −5.1% | −5.6% | +11.3% | +10.4% | +3.4% |
FTDZX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 20.79%
- 3-year Sharpe ratio: 1.13 (vs 4.5% risk-free rate)
- Best month: +19.47% (Dec 2023)
- Worst month: −6.52% (Apr 2024)
FTDZX Fund Flows
Monthly money in and out of Franklin Biotechnology Discovery Fund, from SEC Form N-PORT.
- 12-month net flow: $28.8M
- 12-month gross sales (incl. reinvestments): $249.9M
- Sales ÷ redemptions: 1.13×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $22.9M | $16.8M | $6.2M |
| Jun 2026 | $12.9M | $15.5M | −$2.6M |
| May 2026 | $10.3M | $17.4M | −$7.1M |
| Apr 2026 | $10.0M | $15.0M | −$5.1M |
| Mar 2026 | $8.0M | $15.9M | −$8.0M |
| Feb 2026 | $8.6M | $22.4M | −$13.8M |
| Jan 2026 | $17.0M | $24.3M | −$7.3M |
| Dec 2025 | $113.2M | $32.2M | $81.0M |
| Nov 2025 | $17.5M | $14.6M | $2.9M |
| Oct 2025 | $17.6M | $18.2M | −$587K |
| Sep 2025 | $6.5M | $14.0M | −$7.5M |
| Aug 2025 | $5.4M | $14.9M | −$9.5M |
FTDZX Assets Under Management
Net assets of Franklin Biotechnology Discovery Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $1.15B |
| 2026-04-30 | $1.04B |
| 2026-01-31 | $1.02B |
| 2025-10-31 | $954.14M |
| 2025-07-31 | $726.94M |
| 2025-04-30 | $707.67M |
| 2025-01-31 | $803.15M |
| 2024-10-31 | $896.71M |
| 2024-07-31 | $941.06M |
| 2024-04-30 | $874.79M |
| 2024-01-31 | $896.55M |
| 2023-10-31 | $707.58M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.